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Abstract
The selective entry of nanoparticles into target tissues is the key factor which determines
their tissue distribution. Entry is primarily controlled by microvascular endothelial cells,
which have tissue-specific properties. This study investigated the cellular properties
involved in selective transport of gold nanoparticles (<5 nm) coated with PEG-amine/galac-
tose in two different human vascular endothelia. Kidney endothelium (ciGENC) showed
higher uptake of these nanoparticles than brain endothelium (hCMEC/D3), reflecting their
biodistribution in vivo. Nanoparticle uptake and subcellular localisation was quantified by
transmission electron microscopy. The rate of internalisation was approximately 4x higher
in kidney endothelium than brain endothelium. Vesicular endocytosis was approximately 4x
greater than cytosolic uptake in both cell types, and endocytosis was blocked by metabolic
inhibition, whereas cytosolic uptake was energy-independent. The cellular basis for the dif-
ferent rates of internalisation was investigated. Morphologically, both endothelia had similar
profiles of vesicles and cell volumes. However, the rate of endocytosis was higher in kidney
endothelium. Moreover, the glycocalyces of the endothelia differed, as determined by lec-
tin-binding, and partial removal of the glycocalyx reduced nanoparticle uptake by kidney
endothelium, but not brain endothelium. This study identifies tissue-specific properties of
vascular endothelium that affects their interaction with nanoparticles and rate of transport.
Introduction
Nanoparticles hold great potential in biomedicine; for diagnosis or as carriers of therapeutic
agents to different tissues. However, a central problem is how the nanoparticles can be selec-
tively delivered to the target tissue. Nanoparticles in the blood stream first interact with
vascular endothelium before they may cross or pass the endothelial cells and enter the tissue.
Vascular endothelium in different tissues has distinctive properties including its glycocalyx,
surface receptors, intercellular junctions or rate of production of transport vesicles. These dis-
tinctive properties provide an opportunity to selectively target nanoparticles.
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Most efforts have been directed towards understanding how the properties of the nanoparti-
cle itself may change its interaction with the cell, i.e. whether it is taken up or becomes toxic for
the cell. Several nanoparticle properties have been found to be crucial for this interaction; such
as the size [1–7], shape [3,8,9], charge [7,10–13], ligand coating [14,15] as well as the proteins
that may coat the nanoparticle once it comes into contact with serum [16].
Less attention has been paid to the cellular properties that influence nanoparticle transport.
We have previously shown that glucose-coated gold nanoparticles (covalently bound glucose
with a C2-linker) are transported across endothelium from brain, aorta or bone marrow at dif-
ferent rates [17]. Similarly, other studies have noted different rates of uptake by endothelia of
different origin or epithelia [18–20]. Yet investigations to explain this phenomenon are lacking
even though they may help to achieve tissue-selective targeting of nanoparticles.
Anatomical or physiological differences between different endothelia could explain differ-
ences in nanoparticle uptake and transport rates. In particular, the rate of uptake may be influ-
enced by the plasma membrane properties of the cells and the binding of nanoparticles to cell
surface glycoproteins and proteoglycans, as well as the cells’ capacity for vesicular transport. In
each case, the first step in nanoparticle uptake or transcytosis is an interaction between the api-
cal surface of the endothelial cell and the nanoparticle.
Potentially the first interaction with the endothelial cell will occur between the nanoparticles
and components of the glycocalyx, which extends up to 500 nm from the cell surface [21]. Such
interactions may depend on the cellular proteoglycans and the physical properties of the nano-
particles. This potential interaction is distinct from receptor-mediated binding which may be
promoted by the attachment of specific targeting ligands to the nanoparticle [22], and depends
on the nanoparticle reaching the receptor at the endothelial surface. Non-specific binding to
the endothelium is a key element in absorptive endocytosis which precedes trans-endothelial
transport. Endothelia from different tissues vary in their properties, including the glycocalyx,
surface glycoproteins, receptors and vesicular transport systems, any of which could affect the
rate of nanoparticle binding, internalisation and transcytosis.
Nanoparticles have been proposed as potential carriers of small drugs or biological agents
into different tissues, for example, these can be gold nanoparticles coated with sugars, i.e. glyco-
nanoparticles [23–25]. We have demonstrated that glucose-coated gold nanoparticles cross
human brain endothelium in vitro and they can rapidly enter the brain of rats in vivo, following
intra-vascular injection [17,26]. These studies also demonstrated differential uptake by endo-
thelia from different vascular beds in vitro, and variable distribution to different tissues in vivo.
The current study investigates the cellular basis of these differences, with the ultimate aim
of developing gold nanoparticles that are selective for different tissues, including brain micro-
vessels. Specifically, we have examined cellular characteristics which may account for different
rates of uptake of nanoparticles by human endothelial cells from brain or kidney. These prop-
erties include: (a) the surface glycocalyx; (b) differences in the rates of endocytosis (the sizes of
vesicles and rate of internalisation); or (c) anatomical differences between the cells.
Results and Discussion
Characteristics of the gold nanoparticles
The gold nanoparticles used in this study were coated with equal amounts of PEG-amine and a
galactose derivative (PEG-amine/galactose), which were covalently bound to the gold core by a
thiol linkage (Fig 1). These nanoparticles are similar to those used previously [15]: the galactose
has a C2 linker to the gold core and the PEG-amine is EG6. Nanoparticles coated with PEG-
amine/galactose were much more efficient in entering human brain endothelial cells in com-
parison with nanoparticles coated with galactose alone (Table 1). As the glycocalyx and plasma
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membrane of the endothelium are negatively charged, it has been proposed that cationic nano-
particles may be favoured in cell transport due to electrostatic interactions [27]. Our results
confirm that the cationic PEG-amine/galactose nanoparticles are taken up much more effi-
ciently than uncharged galactose-coated nanoparticles by the endothelium.
Mechanisms of nanoparticle internalisation by endothelium
First, we investigated the mechanism by which PEG-amine/galactose nanoparticles are trans-
ported into the cells. Nanoparticles in different cellular compartments of brain endothelium
were counted and it was noted that a high proportion localised in vesicles (Fig 2A). This
implies that these nanoparticles primarily enter the cells by vesicular transport, an energy-
dependent process. In order to confirm that transport into the brain endothelium was energy-
dependent, the cells were incubated at 4°C (Fig 2B) or in the presence of sodium azide/2-deox-
yglucose (Fig 2C). In both cases the numbers of vesicle-associated nanoparticles was signifi-
cantly reduced. We considered the possibility that these inhibitors of cell metabolism could
affect cell viability. To test this theory, cells were stained with propidium iodide, which only
penetrates cells with damaged membranes: 95% of the cells were not stained (Fig 2D), hence
we concluded that within the time-frame of the experiment, the cell viability was not affected.
Fig 1. Characteristics of PEG-amine/galactose gold nanoparticles. (A) Schematic of nanoparticle
organization. (B) Size distribution of nanoparticles (mean size ± s.d.). (C) High resolution electron microscopy
of <4 nm nanoparticles (scale bar = 5 nm). (D) Absorbance spectrum of the nanoparticles.
doi:10.1371/journal.pone.0161610.g001
Table 1. Internalisation of gold nanoparticles by brain endothelial cells.
Nanoparticle coating Cytosol Vesicles
PEG-amine/galactose 0.26 ± 0.1* 2.07 ± 0.6
Galactose 0.007 ± 0.007 0.0003 ± 0.0001
* Values represent number of nanoparticles per micron of basal membrane from 85 nm TEM sections. Each value is the mean ± standard deviation of 3
independent experiments.
doi:10.1371/journal.pone.0161610.t001
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In addition to nanoparticles that were localised in vesicles, some nanoparticles were present
in the cytosol (Fig 2A). Immediate nanoparticle entry into the cytosol is thought to be energy-
independent. It has been reported previously that gold nanoparticles (~2 nm) can enter the
cytosol of cells by passively crossing the plasma membrane [28–31]. We have also previously
reported that glucose-coated gold nanoparticles cross brain endothelium in vitro via the cyto-
solic route [17,32]. In accordance with these theories, cytosolic localisation of PEG-amine/
galactose nanoparticles was not affected by sodium azide/2-deoxyglucose treatment (Fig 2C).
On the other hand, incubation of the cells at 4°C reduced the number of cytosolic nanoparticles
by about 50% (S1 Fig). This reduction is significant but smaller than the effect of low tempera-
ture on vesicular transport (Fig 2C). Passive uptake may be affected by membrane fluidity
which is highly dependent on temperature—a less fluid membrane could decrease nanoparticle
movement across the plasma membranes. Therefore, a change in membrane fluidity appears to
be the most likely explanation for the reduction in nanoparticles localised in the cytosol at 4°C.
The mechanism of transport in vitro is correlated with observation of nanoparticle transcy-
tosis in vivo (Fig 3). Following intracarotid infusion, nanoparticles are seen in brain microvas-
cular endothelium, primarily in the cytosol. Within 10 minutes of infusion, the nanoparticles
are also detected in cells of the brain parenchyma. Previous work has demonstrated that the
nanoparticles move rapidly within the brain at speeds up to 1μm per minute.
To further analyse the mechanism of transport, brain endothelial cells were treated with
inhibitors during the nanoparticle transport assay. In preliminary experiments nystatin, chlor-
promazine, cytochalasin D and nocodazole were screened for their ability to inhibit the uptake
of 70kDa FITC-dextran by brain endothelium. The doses of inhibitors were equivalent or
Fig 2. Uptake of PEG-amine/galactose gold nanoparticles by brain endothelial cells. (A) Localisation of
nanoparticles at 3hrs (t-test, ** P<0.01). (B) Effect of temperature on nanoparticle uptake into vesicles at
3hrs (t-test, ** P<0.01). (C). Effect of inhibitors of active transport sodium azide/2-deoxy glucose on uptake of
nanoparticles at 2 hrs (one-way ANOVA, Tukey’s post test ** P<0.001). (D) Cell membrane integrity/viability
test after treatment with sodium azide/2-deoxy glucose, for 2 or 4hrs. Digitonin is a positive control for cell
death. All bars showmean ± SEM and are all based on 3-independent experiments.
doi:10.1371/journal.pone.0161610.g002
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greater than those previously reported [15,17] to inhibit endocytosis in non-brain endothe-
lium, however, only nystatin and chlorpromazine were found to significantly inhibit FITC-dex-
tran internalisation in the brain endothelium at the doses used, and in these conditions the
viability of the hCMEC/D3 cells was slightly reduced (S1 Table). Nystatin inhibits caveolar
uptake and chlorpromazine inhibits uptake into clathrin-coated vesicles. The results in the
nanoparticle endocytosis-assay showed a reduction in vesicular uptake of up to 50% by both
inhibitors, however, the difference was not significant due to high variability in cellular uptake
(S2 Fig). Treatment with chlorpromazine significantly increased the number of nanoparticles
in the cytoplasm and nucleus. However, we noted that the shape of the nucleus was irregular
on treated cells. It is possible therefore that chlorpromazine is affecting the permeability of the
plasma and nuclear membranes as well as cytoplasmic transport systems.
Fig 3. Location of PEG-amine/galactose nanoparticles in a brain vessel in vivo. Silver-enhanced electron
micrograph of a microvessel of rat cerebral cortex, 10 minutes after intracarotid infusion of 50 μg (Au) of
nanoparticles. Arrows indicate nanoparticles in the endothelium. Scale bar = 500 nm.
doi:10.1371/journal.pone.0161610.g003
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Comparison of uptake by brain and kidney endothelium
We then investigated the rate of nanoparticle uptake in different endothelial cells. For this pur-
pose we selected two human endothelial cell lines, from brain and kidney. The choice of cells
was based on observations in vivo which showed that nanoparticles accumulated at highest lev-
els in the kidney, and lowest in brain 10 minutes after intravascular infusion (S3 Fig). Initially,
we hypothesised that the higher rate of accumulation in the kidney was related to structural dif-
ferences such as fenestrations in kidney endothelium and tight junctions in brain endothelium.
Alternatively, the difference could be due to surface properties of the endothelium or their
rates of transcytosis.
The brain endothelial cell line hCMEC/D3 and the kidney glomerular endothelial line
ciGENC are well characterised cells [33,34]. Both were immortalised by a similar process,
involving transfection with SV40 large-T and both retain many of their tissue-specific proper-
ties. When we compared the uptake of PEG-amine/galactose nanoparticles in both endothelial
cells, kidney endothelium showed higher nanoparticle uptake than brain endothelium, both
into vesicles and cytosol (Figs 4 and 5). Both endothelial cell types showed approximately 4
times more nanoparticles in vesicles than in the cytosol. In both brain and kidney endothelium,
there is an accumulation of nanoparticles on the transwell membrane, beneath the basal plasma
membrane of the cells. These results imply that the nanoparticles have crossed the endothelium
by cytosolic or vesicular transcytosis, and have been retained on the negatively charged filter.
The role of the endothelial glycocalyx in nanoparticle internalisation
To explain the higher uptake of the nanoparticles by kidney endothelium we considered 3 pos-
sible mechanisms: (a) the surface properties of the endothelium are different so that the initial
binding of the nanoparticles to the cells varies; (b) the rate of endocytosis is comparatively low
in the brain endothelium; (c) morphological features of the cell lines, such as vesicle numbers
or size of the cells may differ between the endothelia.
The initial interaction of a nanoparticle with the endothelium may occur at the glycocalyx.
The glycocalyx is a brush-like structure that is located on the apical side of vascular endothelial
cells. Its size can range from 0.5 microns to 11 microns deep [35–38] and it contains glycopro-
teins and proteoglycans which consist of glycosaminoglycans attached to core polypeptides.
The glycocalyx is thought to be more fully developed in vivo than in vitro [39] and it is strongly
Fig 4. Uptake of nanoparticles by kidney or brain endothelial cells. Internalisation of PEG-amine/
galactose gold nanoparticles into vesicles or cytosol of brain (hCMEC/D3) or kidney (ciGENC) endothelial
cells at 3 hrs. Data are mean ± SEM of 3 independent experiments (ANOVA followed by Tukey’s multiple
comparison test, P<0.01).
doi:10.1371/journal.pone.0161610.g004
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negatively-charged, particularly on brain endothelium [40]. To investigate the role of the glyco-
calyx, we carried out a lectin-binding assay on the kidney and brain endothelium. Lectins bind
to specific carbohydrate residues on the glycocalyx (Table 2) and they can be used to identify
changes in glycocalyx composition [41]. They can also identify specialised domains on the
plasma membrane [42].
The lectin Ulex Europaeus agglutin (UEA) was used as a standard marker for endothelium
[43]. The other three lectins were found to bind human endothelial cells in an initial screening
of a panel of 23 lectins, of which 15 bound strongly to a panel of human endothelia (S2 Table).
Wheat germ agglutinin (WGA) recognises N-acetyl glucosamine, including terminal sialic acid
residues, whereas peanut agglutinin (PNA) andWisteria floribunda lectin (WFL) primarily
recognise internal residues. A schematic illustration of the proposed arrangement of the major
lectin binding site, based on data in this study is shown in supplementary material (S4 Fig).
Wheat germ agglutinin and peanut agglutinin have been shown to bind to microdomains of
endothelium which are associated with transport vesicles (‘plasmalemmal vesicles’) [42]. We
found that kidney endothelium exhibited a stronger binding profile to all lectins in comparison
with brain endothelium (Fig 6A). This implies that the glycocalyx does indeed differ between
the two cell types, and suggests that the kidney endothelium has higher numbers of domains
associated with endocytosis.
Table 2. Glycan-binding properties of lectins on endothelium.
Lectin Sugar speciﬁcity
Ulex Europaeus agglutinin (UEA) -αL-fucose
Peanut agglutinin (PNA) Gal-β(1–3)-GalNac
Wisteria Floribunda lectin (WFL) GalNac
Wheat germ agglutinin (WGA) GlcNac
doi:10.1371/journal.pone.0161610.t002
Fig 5. TEM of PEG-amine/galactose nanoparticles in endothelial cells. Silver-enhanced nanoparticles in
endothelial cells, 3 hrs after their application to the apical (upper) cell surface. (A) Brain endothelial cells,
hCMEC/D3. (B) Kidney endothelial cells, ciGENC. Scale bar = 0.5 μm.
doi:10.1371/journal.pone.0161610.g005
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To further analyse the role of the glycocalyx, enzymatic digestion was used to selectively
remove carbohydrate residues. For partial removal of the glycocalyx we used neuraminidase
and O-sialoglycoprotein endopeptidase (OSGEP). Neuraminidase removes sialic acid residues
which contribute to the net negative charge of the glycocalyx, whereas the endopeptidase
removes core polypeptides that have bound carbohydrate units. The lectin binding was
changed by these enzymes (S5 Fig) confirming that elements of the glycocalyx, including the
terminal sialic acid residues recognised by WGA, were removed. Chondroitinase and hepari-
nase were also tested but they did not consistently affect lectin binding (data not shown). Nei-
ther neuraminidase nor endopeptidase treatment caused any change in the uptake of PEG-
amine/galactose nanoparticles either into the cytosol or vesicles of brain endothelium (Fig 6B).
However, neuraminidase produced a small reduction and endopeptidase a significant reduc-
tion in nanoparticle uptake by the kidney endothelium (Fig 6C).
Initially, we hypothesised that removal of the negatively charged sialic acid residues by
neuraminidase would increase nanoparticle uptake, by allowing the cationic nanoparticles to
reach the plasma membrane more rapidly and thus enhance endocytosis. Therefore, the
reduction in nanoparticle uptake following endopeptidase treatment was contrary to this
hypothesis. One possible explanation is that the endopeptidase treatment disrupts microdo-
mains (i.e. membrane subregions) which form the endocytotic vesicles, thus reducing endocy-
tosis. The reduced nanoparticle uptake is only seen with kidney endothelium which has both
higher levels of endocytosis as well as higher levels of lectin-binding sites than brain endothe-
lium (Figs 6 and 7A).
The effect of the endothelial glycocalyx on nanoparticle uptake has not been investigated
previously. The glycocalyx of erythrocytes has been shown to be crucial to the attachment of
amphiphilic gold nanoparticles (around 2 nm core) to the cell membranes [44]. In this study,
neuraminidase had a large effect on the nanoparticle attachment that was only slightly
increased by treating with a combination of enzymes [44]. It is likely that fundamental
Fig 6. Effect of the endothelial glycocalyx on nanoparticle internalisation. (A) Binding profile of lectins
WGA,WFL and PNA on brain and kidney endothelium. Binding was standardised as a percentage of UEA
(standard endothelial marker), showing the mean ± SEM from 3 independent experiments (ANOVA and
Tukey’s multiple comparison test, *** P<0.001). Effect of partial removal of glycocalyx (with neuraminidase
or endopeptidase) on nanoparticle uptake into cytosol or vesicles, of brain endothelium (B) or kidney
endothelium (C), compared with untreated cells (= 100%). (Data shown are mean ± SEM from 3 independent
experiments, paired t-test, * P<0.05).
doi:10.1371/journal.pone.0161610.g006
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differences in levels of endocytosis by erythrocytes and endothelium as well as the differences
in the glycocalyx and use of different nanoparticles can explain why the endothelium takes up
these nanoparticles so effectively by comparison with erythrocytes. It has been previously
established that there is a 20 nm gap between each proteoglycan chain on the endothelial glyco-
calyx [45], which may allow smaller nanoparticles to freely pass through to the membrane
surface.
Differences in the rate of endocytosis, affecting nanoparticle uptake
We next investigated whether the different transport rates of the endothelia could be primarily
due to differences in their overall rate of endocytosis, rather than the rate of nanoparticle bind-
ing. The rate of endocytosis can be investigated by loading cells with FITC-dextrans of different
size. We selected FITC-dextran of 10 kDa and 70 kDa size, which correspond to a diameter of
4.4 nm and 12 nm, respectively [46]. Kidney endothelium showed higher fluorescence intensity
when treated with both FITC-dextrans (Fig 7A) in comparison with brain endothelium. This
may mean that the kidney endothelium has larger vesicles or has more vesicles because it is a
larger cell. Firstly, we investigated vesicular radius and distribution of vesicles. However, we
found that the mean vesicular radius was no different (Fig 7B) and both endothelia had a simi-
lar profile of vesicle sizes (S6 Fig). Secondly, as brain and kidney endothelial cells differ mor-
phologically, we also investigated the cell volumes, but again we found that they were not
significantly different (S7 Fig). Thus we concluded that the higher fluorescence intensity of
FITC-dextran is due to a higher rate of endocytosis by kidney endothelium.
Taken together, these results show that the high rate of nanoparticle uptake by kidney endo-
thelium may be explained by its higher rate of endocytosis. This may be correlated with its high
level of surface lectin-binding domains, which are associated with endocytotic vesicles. In vivo
endothelial cells show even more marked tissue-specific characteristics. Specifically, brain
endothelium in vivo has very low numbers of transport vesicles (caveolae) by comparison with
other endothelia. While other factors may affect transport into tissues, it is nonetheless the
endothelium which controls the initial uptake of nanoparticles to each tissue and hence the
endothelium is likely to be the critical cell type in determining the rate of nanoparticle entry
into different tissues. This is particularly true for smaller nanoparticles which are not cleared
by the mononuclear phagocyte system.
In summary, we have shown that galactose/PEG-amine-gold nanoparticles are actively taken
up by brain and kidney endothelium primarily into vesicles. Smaller numbers enter the cells
Fig 7. Comparison of the rate of endocytosis and vesicular size in endothelial cells. (A) Endocytosis of
dextran measured by FACS, after 1hr incubation, comparing brain and kidney endothelial cells (mean ± SEM,
3 independent experiments, repeated-measures ANOVA with Bonferroni multiple comparison post test, * P<
0.05). (B) Diameter of vesicles in brain and kidney endothelial cells (mean ± SEM of 3 independent
experiments, unpaired t-test, no-significant difference).
doi:10.1371/journal.pone.0161610.g007
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passively via the cytosolic route, crossing the plasma membrane. The rate of uptake was higher
into kidney endothelial cells in comparison with brain endothelial cells. This is best explained by
the higher overall rate of endocytosis by the kidney endothelium. The glycocalyx was also differ-
ent between brain and kidney endothelium. Hence the possibility that the endothelial glycocalyx
restricts nanoparticle access to the cell surface was investigated. However, partial removal of the
glycocalyx actually reduced the rate of nanoparticle uptake by the kidney endothelium although
it had no effect on nanoparticle uptake by brain endothelium. Thus, the glycocalyx does not
appear to act as a barrier to these nanoparticles. Indeed disrupting the surface proteoglycans of
kidney endothelium unexpectedly reduced nanoparticle internalisation. Consequently, it appears
that the rate of endocytosis, rather than cell surface binding, is the main factor accounting for the
different rates of nanoparticle internalisation by the different endothelia.
Conclusions
Most research into the interactions of nanoparticles with cells has been concerned with how
properties of the nanoparticles affect the cell. This study demonstrates how properties of the
cell can influence nanoparticle uptake. We based our study on the observation of selective
uptake of gold nanoparticles by human kidney endothelium in comparison with brain endo-
thelium, since endothelial cells primarily determine the rate of entry of nanoparticles into dif-
ferent tissues. We concluded that gold nanoparticle uptake is correlated with the cell’s potential
for active endocytosis. In addition, the surface glycocalyx affected active uptake of nanoparti-
cles, but only for kidney endothelium. These findings in vitro reflect the tissue distribution of
these small gold nanoparticles in vivo. Our work highlights the need to carry out detailed analy-
sis of cell behaviour, in order to assess the potential use of nanoparticles as cell-selective or
tissue-targeted carriers. Detailed analysis of both endocytosis and the interactions between
nanoparticles and cell surface proteoglycans and glycoproteins may improve the design of such
carriers. This information can help predict nanoparticle behaviour in the body.
Materials and Methods
Nanoparticle synthesis, characterisation and toxicity assessment
Gold nanoparticles were synthesized essentially as described previously [15]. Briefly, the
organic ligand coating for this gold nanoparticle was comprised of two ligands: 1-thiohexaethy-
lene glycol-17-ammonium acetate (Galchimia, Spain) and 2-thioethyl α-D-galactopyranoside
as the disulphide (Galchimia, Spain). A 50:50 ligand starting ratio was used at the time of
reduction of HAuCl4 with NaBH4 in 90% methanol and 10% water, with a 3-fold molar excess
of total ligands to gold. After 2 hr shaking the nanoparticles were purified from unbound
ligands and reactants by washing them 4x with excess water using a Millipore 10kDa ultra-cen-
trifugation device. The nanoparticles were resuspended in water acidified to pH 6 with acetic
acid and stored at 4°C prior to use.
The nanoparticle size was analysed using a transmission electron microscope (TEM). The
nanoparticle solution was air-dried on a copper mesh grid slot and viewed on a JEM 1400
(JEOL, Japan) at an acceleration voltage of 80 kV and magnification of 80,000X. The images
were analysed using ImageJ. The characteristic atomic mesh of the nanoparticles was observed
on a high resolution TEM JEM 2100 (JEOL, Japan) at an acceleration voltage of 150 kV and
magnification of 150,000X. The absorption spectrum of these nanoparticles was determined
using a SPECTROstar Nano spectrophotometer (BMG Labtech, Germany).
The toxicity of PEG-amine/galactose gold nanoparticles was assessed on cells grown in
96-well plates. The nanoparticles were incubated with brain endothelial cells (hCMEC/D3) for
48 hrs at concentrations of up to 75 μg/ml at 37°C, with 4 replicates per treatment. The cells
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were then washed 2x with HBSS (Hank’s balanced salt solution, Sigma) and MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was added to the cultures for 3.5 hrs
at 37°C. The solution was aspirated and 100 μl of DMSO (dimethylsulfoxide) was added to
each well. The plate was then shaken for 10 min and the absorbance was read at 540 nm on a
plate reader OPTIMA FluoStar (S8 Fig).
Cell cultures
The immortalized brain endothelial cell line, hCMEC/D3 [47], was propagated in EBM-2 MV
medium with 2.5% foetal bovine serum, 0.025% VEGF, IGF and EGF; 0.1% bFGF, gentamycin,
amphotericin B and ascorbic acid; 0.04% hydrocortisone. The medium was changed every 2–3
days and the cells cultured between passages 25 and 33. The cells were kept at 37°C in humidi-
fied atmosphere with 5% CO2.
The conditionally immortalized glomerular endothelial cells (ciGENC) were supplied by
Simon Satchell [33]. They were propagated in EBM-2 MV supplemented according to the
manufacturer’s protocol, with the exception of growth factor VEGF, which was omitted from
the medium. The medium was changed every 2–3 days. The propagating cultures were grown
at 33°C. For experiments the cultures were kept at 33°C until they were 90% confluent, then
they were kept at 37°C for 3–5 days in order to develop kidney glomerular endothelial pheno-
type before they were used. In each case, the cells were kept in a humidified atmosphere with
5% CO2. In all assays the different endothelial cells were cultured in identical conditions.
Cell viability following antibiotic treatment was measured by trypan blue exclusion. The
hCMEC/D3 cells (105) were stained with 0.04% trypan blue in PBS and the percentage of
stained (non-viable) cells counted. The background percentage of non-viable cells in untreated
cultures was subtracted from the values stated.
To assess the active uptake involvement in transport of PEG-amine/galactose gold nanopar-
ticles, the hCMEC/D3 cells were cultured for 3 hrs at 4°C or for 2 hrs with inhibitors of active
metabolism NaN3 (10 mM) + 2-deoxyglucose (50 mM) and processed for TEM (see below).
The possible cytotoxic effect of NaN3 + 2-deoxyglucose on cells was assessed by staining cells
with propidium iodide after 2 or 4 hr treatment. Digitonin (30 μg/ml for 15 min) was used as a
positive control for cell death, and fluorescence intensity was measured on a Facscan, channel
FL2 set at 400V gain: 10,000 events were analysed from the gated cell population.
Transmission electron microscopy to quantify the localisation and
number of nanoparticles in cells
The rate of transport of PEG-amine/galactose gold nanoparticles into and across cells was
assessed by quantification of the number of nanoparticles in cells by transmission electron
microscopy (TEM). The cells were grown on transwell inserts (1 cm2, Corning Costar), the
nanoparticles (8 μg/ml) were applied to the top chamber in EBM-2 MVmedium supplemented
with 2.5% FBS. The time of incubation was 2–3 hrs. After the incubation, both chambers were
washed 3x in HBSS. The cells were fixed in 2.5% glutaraldehyde for 1 hr at room temperature.
The fixative was removed, both chambers washed 3x in PBS (phosphate buffer saline) and
stored in phosphate buffer at 4°C.
The samples were processed for TEM (all incubations were performed at room temperature
and all solutions were applied to both the insert and the bottom chamber). Firstly, the cells
were permeabilized in 0.01% Triton x100 for 15 minutes on a rocker. The inserts were washed
3x in PB (phosphate buffer) and silver enhanced. Silver enhancement (Aurion) was prepared
according to the manufacturer’s protocol and applied to the insert for 45 min. 3 washes in dis-
tilled water followed. The cells were then treated with 1% osmium tetroxide for 30 min. The
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insert was washed 3x in PB and removed from the well; the membrane was cut in 2 pieces of
about 2 x 3 mm each. The membranes were then gradually dehydrated in ethanol: 30% and
50% for 5 min, 70% and 90% for 10 min, 100% for 10 min twice, 100% with molecular sieve for
10 min. The membranes were incubated in a 50:50 mixture of 100% ethanol and Epon resin
overnight and then in fresh resin twice for 2 hrs. The embedding took place at 60°C for 48 hrs.
Resin blocks were microsectioned to 80 nm sections using a Diamond knife (Diatome, Switzer-
land). The sections were collected onto pioloform film-covered copper grids. They were stained
in 1% uranyl acetate (30 min) followed by lead citrate (10 min). Sections were viewed on a JEM
1010 (Jeol, Japan) at an acceleration voltage of 80 kV. The cells were observed at magnification
of 20,000x which allowed sufficient magnification to view the nanoparticles. The nanoparticles
were counted and sorted into categories “vesicles” or “cytosol” during viewing on the electron
microscope. The length of insert which was viewed (usually around 1000 microns in length)
was measured with low magnification of 150X and the number of nanoparticles was recalcu-
lated to obtain number of nanoparticles per micron of insert.
Characterisation and modulation of the endothelial glycocalyx
In order to characterise the endothelial glycocalyx, cells were stained using biotinylated lectins.
hCMEC/D3 cells or ciGENC cells were cultured in a 96 well plate for 3 and 4 days respectively.
The cells were washed twice in HBSS, fixed in 0.1% glutaraldehyde (in PBS) for 15 min. They
were washed twice in PBS, blocked in 0.05M Tris/HCl for 20 min and washed 3x in wash buffer
(0.05% Tween20 in PBS). Lectins were added for 1 hr at concentrations: Ulex Europaeus agglu-
tinin 10 μg/ml, Wheat germ agglutinin 5 μg/ml, Peanut agglutinin 20 μg/ml,Wisteria flori-
bunda lectin 20 μg/ml; all prepared in diluent (5 mg/ml BSA and 0.01% Tween20 in PBS).
After the incubation, the cells were washed in wash buffer 3x. Streptavidin peroxidase (1:700 in
5 mg/ml BSA and 0.01% Tween20 in PBS) was added to the cells for 1hr, then washed in wash
buffer 3X and once in PBS. The chromogen solution containing 100 μg/ml tetramethylbenzi-
dine in 0.1M sodium acetate/citric acid was prepared and hydrogen peroxide added to a final
concentration of 1/3000. This solution was added to the cells for 10–15 min resulting in blue
colour; the reaction was stopped by adding 20 μl of 30% H2SO4 per well. The absorbance was
read at 450 nm on a plate reader OPTIMA FluoSTAR. Data are expressed as mean absorbance
from replicate wells, of a representative experiment, which had been repeated 3 times.
Endothelial cells were also treated with enzymes for 2 hrs, to remove parts of the glycocalyx.
The enzymes used were 50 mU/ml neuraminidase or 25 μg/ml endopeptidase. After the treat-
ment, the cells were washed twice in HBSS and either stained with lectins or treated with nano-
particles (as described above).
Analysis of rate of endocytosis
The cells were treated with FITC-dextran of 70 kDa or 10 kDa in order to test the rate of endo-
cytosis. The cells were grown in 12-well plates and FITC-dextran was applied at 0.2 mg/ml for
1 hr. The cells were washed with ice-cold HBSS 5x over 5 min; they were trypsinized, collected
and washed 2x in HBSS + 0.1 mg/ml BSA. Then they were resuspended in PBS and analysed
using flow cytometry (BD FacScan, channel FL1, 460#x2014;500V: 10,000 events analysed
from the gated cell population). Data are expressed as the mean of the median fluorescence val-
ues from 3 independent experiments.
Analysis of vesicular diameter and cell volume
TEM sections of hCMEC/D3 and ciGENC cells were used to analyse vesicular diameter and
cell volume. Each section corresponded to a well with a single treatment. As each treatment
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had 3 wells, one was randomly picked for this analysis and 3 independent experiments were
analysed per cell type, resulting in 3 sections analysed altogether. At 20,000x magnification on
JEM 1010 (Jeol, Japan), about 100 vesicular diameters were measured per section in cells that
were randomly picked. The data set was analysed with Microsoft Office Excel 2010 and Graph-
Pad Prism. Similarly, to obtain volumes of brain cells in comparison to kidney cells, 3 indepen-
dent experiments were analysed for each cell type. At magnification of 2,000X on JEM 1010
(Jeol, Japan) 10 images per treatment were taken randomly. The cell area was measured using
ImageJ. The data were analysed as a distribution histogram and means of each independent
experiment were calculated and analysed by GraphPad Prism.
In vivo study of nanoparticle tissue-distribution
For the animal study, 4 adult male Wistar albino rats weighing 250–300 g were used (Vivarium
from Bogazici University, Istanbul, Turkey) for testing nanoparticle distribution.
This work was approved by the Local Ethics Committee for Animal Experimentation of
Istanbul University (2014/06).
The animals were anaesthetized with chloral hydrate (360 mg/kg, i.p.) and locally anaesthe-
tized with bupivacaine hydrochloride. After the incision in the neck, the left common internal
and external carotid arteries were exposed. The external carotid was ligated and the artery was
retrogradely catheterized. Each animal was infused with warm 50 μg (100 μl) of nanoparticle
solution (prepared in water) through the exposed external carotid artery over 2 min using an
infusion pump (Harvard Apparatus, Infusion/Withdrawal pump, Model No: 901A). The nano-
particles were allowed to circulate for 10 min and the animals were administered with sodium
pentothal (50 mg/kg, i.p.) and chloral hydrate (100 mg/kg, i.p.) before perfusion/fixation proce-
dure. The animals were perfused transcardially with 0.9% saline (75 ml), and fixed with 200 ml
of 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M PB for 15 min. The brain, liver, kid-
ney and lung were collected and stored for the analysis.
To analyse the amount of gold in the organs, ICP-MS (inductively-coupled plasma massed
spectrometry) was used. Boiling HNO3 was used to digest brain, liver, kidney and lung for
5–10 min. After diluting the samples to 5 ml volume, they were run in 1% HCl with Iridium
standard (10 ng/ml) on NexION ICP-MS (PerkinElmer, USA). The ICP-MS produced data on
the amount of gold per gram of tissue. In order to account for the differences in individual size
(body weight) of the animals, these values were compensated according to the weight of each
animal, resulting in relative levels of gold in each tissue.
Supporting Information
S1 Fig. Uptake of cytosolic nanoparticles at 4°C compared with 37°C (= 100%).Data show
mean ± SEM of 3 independent experiments. Unpaired t-test,  P< 0.01.
(TIF)
S2 Fig. Inhibition of nanoparticle active transport by antibiotics. Brain endothelial cells
(hCMEC/D3) were treated with 30μg/ml chlorpromazine or 50μg/ml nystatin during a nano-
particle uptake assay for 1hr. Results show mean ± SEM of 2-independent experiments, com-
paring treated and untreated cells.  P<0.05.
(TIF)
S3 Fig. In vivo uptake of PEG-amine/galactose—gold nanoparticles in rat tissues following
infusion into the carotid artery. Nanoparticles were allowed to circulate for 10 minutes before
perfusion to remove nanoparticles from the vasculature. Gold was measured by ICP-mass
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spectrometry. Values are mean ± SEM of 4 animals.
(TIF)
S4 Fig. A scheme for lectin binding sites on endothelial cells. PNA = peanut agglutinin,
WFL =Wisteria floribunda lectin, WGA =Wheat germ agglutinin. Neuraminidase removes
the terminal sialic acid to reduce binding of WGA and enhance binding of PNA and WFL (See
S5 Fig).
(TIF)
S5 Fig. Test of enzymatic removal of glycocalyx on kidney and brain endothelial cells. Bind-
ing of lectin PNA (A) and (C) to glycocalyx of kidney (A) and brain endothelial cells (C) after
enzymatic removal with endopeptidase (endo) or neuraminidase (neura). Binding of lectin
WGA (B) and (D) to kidney (B) and brain endothelial cells (D) after enzymatic removal with
endopeptidase and neuraminidase. ANOVA Tukey’s multiple comparison P<0.05, P<0.01,
P<0.001. Data shown as mean ± SEM of 3 independent experiments.
(TIF)
S6 Fig. A profile analysis of vesicular diameter for brain (A) and kidney (B) endothelial
cells.
(TIF)
S7 Fig. Comparison of cell volume area of brain (hCEMC/D3) and kidney (ciGENC) endo-
thelial cells. The cell volume area was analysed from sections viewed on the electron microscope.
3 independent experiments, data shown as mean +-SEM, t-test non-significant.
(TIF)
S8 Fig. In vitro toxicity of gold nanoparticles on brain endothelial cells (hCMEC/D3).MTT
assay of nanoparticles coated with PEG-amine/galactose of varying concentrations at 48 hrs
exposure to the cells (n = 3). Digitonin treatment is a control of cell death. Data shown as mean
±SEM.
(TIF)
S1 Table. Viability of hCMEC/D3 cells treated with antibiotics. Viability was measured by
trypan blue staining. Results are mean ±SD from 3 independent experiments with duplicate
determinations.
(DOCX)
S2 Table. Initial screen of lectin-binding to human endothelial cells. Binding of biotinylated
lectins (10μg/ml) was compared with the level of binding of 5 μg/ml antibody to MHC class-I
(standard). Results are from 3 experiments and are expressed as the binding range for each lec-
tin, where— = no detectable binding, 1 =<25%, 2 = 25%-75%, 3 = 75%-125%, 4 = 125%-175%
and 5 =>175% of the MHC class-I. Lectins used were: ConA, concanavalin-A; DBA, Dolichus
biflorus agglutinin; DSL, Daturum stramonium lectin; ECL, Erythina crystagalli lectin; GSL,
Griffonia (Bandeiraea) simplificifolia lectins I, II and isolectin B4; Jacalin; LCA, Lens culinaris
agglutinin; LEL, Lycopersicon esculentum (tomato) lectin; PHA-E, Phaseus vulgaris erythroag-
glutinin; PHE-L, Phaseus vulgaris leucoagglutinin; PNA, peanut agglutinin; PSA, Pisum
sativum agglutinin; RCA1, Ricinus communis agglutinin; SBA, Soybean agglutinin; SJA,
Sophora japonica agglutinin; STL, Solanum tubersosum (potato) lectin; UEA I, Ulex europaeus
agglutin I; VVL, Vicia villosa lectin; WFL, Wisteria floribunda lectin; WGA, Wheat germ
agglutinin; sWGA, succinylated wheat germ agglutinin. Human endothelial cells were prepared
as described (Hillyer P and Male DK (2005) Expression of chemokines on the surface of differ-
ent human endothelia. Immunol. Cell Biol. 83, 375–382) and those used were: BMEC, Bone
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marrow endothelial cells; SVEC, saphenous vein endothelial cells; HUVEC, human umbilical
vein endothelial cells; DMVEC, dermal microvascular endothelial cells; LMVEC, lung micro-
vascular endothelial cells.
(DOCX)
Acknowledgments
The authors thank Canan Ugur Yilmaz and Nurcan Orhan for their contribution to the in vivo
work; Ibon Perera and Julen Barrenetxea fromMidatech Pharma for ICP-MS analysis. Philippa
Hillyer carried out the initial screening of the panel of lectins on human endothelial cells.
Author Contributions
Conceptualization: DMMK IAR.
Formal analysis: RG DM.
Funding acquisition: BS DM.
Investigation: RGMK PW.
Methodology: RG DMMK.
Project administration: DM.
Resources: IAR SCS.
Supervision: IAR BS.
Validation: RGMK DM.
Visualization: RG DM.
Writing – original draft: RG DM.
Writing – review & editing: RGMK IAR PW SCS BS DM.
References
1. JiangW, Kim BYS, Rutka JT, ChanWCW. Nanoparticle-mediated cellular response is size-dependent.
Nat Nanotechnol. 2008; 3: 145–50. doi: 10.1038/nnano.2008.30 PMID: 18654486
2. Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S. Size-Dependent Endocytosis of Nanoparticles. Adv
Mater. 2009; 21: 419–424. doi: 10.1002/adma.200801393 PMID: 19606281
3. Chithrani BD, Ghazani A a, ChanWCW. Determining the size and shape dependence of gold nanopar-
ticle uptake into mammalian cells. Nano Lett. 2006; 6: 662–8. doi: 10.1021/nl052396o PMID: 16608261
4. Osaki F, Kanamori T, Sando S, Sera T, Aoyama Y. A quantum dot conjugated sugar ball and its cellular
uptake. On the size effects of endocytosis in the subviral region. J Am Chem Soc. 2004; 126: 6520–1.
doi: 10.1021/ja048792a PMID: 15161257
5. Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, et al. Superior penetration and retention behavior of 50 nm
gold nanoparticles in tumors. Cancer Res. 2013; 73: 319–330. doi: 10.1158/0008-5472.CAN-12-2071
PMID: 23074284
6. Ma X, Wu Y, Jin S, Tian Y, Zhang X, Zhao Y, et al. Gold nanoparticles induce autophagosome accumu-
lation through size-dependent nanoparticle uptake and lysosome impairment. ACS Nano. 2011; 5:
8629–8639. doi: 10.1021/nn202155y PMID: 21974862
7. Jiang Y, Huo S, Mizuhara T, Das R, Lee Y-W, Hou S, et al. The Interplay of Size and Surface Function-
ality on the Cellular Uptake of Sub-10 nmGold Nanoparticles. ACS Nano. 2015; 10: 9986–9993. doi:
10.1021/acsnano.5b03521
Transport of Gold Nanoparticles by Vascular Endothelium
PLOSONE | DOI:10.1371/journal.pone.0161610 August 25, 2016 15 / 17
8. Chithrani BD, ChanWCW. Elucidating the mechanism of cellular uptake and removal of protein-coated
gold nanoparticles of different sizes and shapes. Nano Lett. 2007; 7: 1542–50. doi: 10.1021/nl070363y
PMID: 17465586
9. Yang K, Ma Y-Q. Computer simulation of the translocation of nanoparticles with different shapes across
a lipid bilayer. Nat Nanotechnol. Nature Publishing Group; 2010; 5: 579–583. doi: 10.1038/nnano.2010.
141
10. Arvizo RA, Miranda OR, ThompsonMA, Pabelick CM, Bhattacharya R, Robertson DJ, et al. Effect of
nanoparticle surface charge at the plasmamembrane and beyond. Nano Lett. 2011; 10: 2543–2548.
11. Han H-S, Martin JD, Lee J, Harris DK, Fukumura D, Jain RK, et al. Spatial Charge Configuration Regu-
lates Nanoparticle Transport and Binding Behavior In Vivo. Angew Chemie Int Ed. 2013; 52: 1414–
1419.
12. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010; 6: 12–
21. doi: 10.1002/smll.200901158 PMID: 19844908
13. Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, Mukherjee P. Mechanism of anti-angio-
genic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine Nano-
technology, Biol Med. Elsevier Inc.; 2011; 7: 580–587. doi: 10.1016/j.nano.2011.01.011
14. Verma A, Uzun O, Hu Y, Hu Y, Han H-S, Watson N, et al. Surface-structure-regulated cell-membrane
penetration by monolayer-protected nanoparticles. Nat Mater. 2008; 7: 588–95. doi: 10.1038/
nmat2202 PMID: 18500347
15. Lund T, Callaghan MF, Williams P, Turmaine M, Bachmann C, Rademacher T, et al. The influence of
ligand organization on the rate of uptake of gold nanoparticles by colorectal cancer cells. Biomaterials.
Elsevier Ltd; 2011; 32: 9776–84. doi: 10.1016/j.biomaterials.2011.09.018
16. Walkey CD, ChanWCW. Understanding and controlling the interaction of nanomaterials with proteins
in a physiological environment. Chem Soc Rev. The Royal Society of Chemistry; 2012; 41: 2780–99.
doi: 10.1039/c1cs15233e
17. Gromnicova R, Davies HA, Sreekanthreddy P, Romero IA, Lund T, Roitt IM, et al. Glucose-coated gold
nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PLoS One. 2013;
8: e81043. doi: 10.1371/journal.pone.0081043 PMID: 24339894
18. Freese C, Unger RE, Deller RC, Gibson MI, Brochhausen C, Klok H-A, et al. Uptake of poly(2-hydroxy-
propylmethacrylamide)-coated gold nanoparticles in microvascular endothelial cells and transport
across the blood-brain barrier. Biomater Sci. 2013; 1: 824–833.
19. Albanese A, ChanWCW. Effect of Gold Nanoparticle Aggregation on Cell Uptake and Toxicity. ACS
Nano. 2011; 5: 5478–5489. Available: http://pubs.acs.org/doi/abs/10.1021/nn2007496 doi: 10.1021/
nn2007496 PMID: 21692495
20. Freese C, Uboldi C, Gibson MI, Unger RE, Weksler BB, Romero I a, et al. Uptake and cytotoxicity of cit-
rate-coated gold nanospheres: Comparative studies on human endothelial and epithelial cells. Part
Fibre Toxicol.???; 2012; 9: 23. doi: 10.1186/1743-8977-9-23 PMID: 22759355
21. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer.
Annu Rev Biomed Eng. 2007; 9: 121–67. doi: 10.1146/annurev.bioeng.9.060906.151959 PMID:
17373886
22. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Büchel C, et al. Human serum albumin nanopar-
ticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug
Target. 2010; 18: 842–8. doi: 10.3109/1061186X.2010.513712 PMID: 20849354
23. Reichardt NC, Martín-Lomas M, Penadés S. Glyconanotechnology. Chem Soc Rev. 2013; 42: 4358.
doi: 10.1039/c2cs35427f PMID: 23303404
24. García I, Marradi M, Penadés S. Glyconanoparticles: multifunctional nanomaterials for biomedical
applications. Nanomedicine (Lond). 2010; 5: 777–792. doi: 10.2217/nnm.10.48
25. Chiodo F, Marradi M, Calvo J, Yuste E, Penadés S. Glycosystems in nanotechnology: Gold glyconano-
particles as carrier for anti-HIV prodrugs. Beilstein J Org Chem. 2014; 10: 1339–46. doi: 10.3762/bjoc.
10.136 PMID: 24991287
26. Gromnicova R, Yilmaz CU, Orhan N, Kaya M, Davies H, Williams P, et al. Localisation and mobility of
glucose-coated gold nanoparticles within the brain. Nanomedicine (Lond). 2016;in press. Available:
http://www.ncbi.nlm.nih.gov/pubmed/19437620
27. Cho EC, Xie J, Wurm P a., Xia Y. Understanding the role of surface charges in cellular adsorption ver-
sus internalization by selectively removing gold nanoparticles on the cell surface with a I 2/KI etchant.
Nano Lett. 2009; 9: 1080–1084. doi: 10.1021/nl803487r PMID: 19199477
28. Van Lehn RC, Atukorale PU, Carney RP, Yang Y-S, Stellacci F, Irvine DJ, et al. Effect of particle diame-
ter and surface composition on the spontaneous fusion of monolayer-protected gold nanoparticles with
lipid bilayers. Nano Lett. 2013; 13: 4060–7. doi: 10.1021/nl401365n PMID: 23915118
Transport of Gold Nanoparticles by Vascular Endothelium
PLOSONE | DOI:10.1371/journal.pone.0161610 August 25, 2016 16 / 17
29. Van Lehn RC, Alexander-Katz A. Fusion of Ligand-Coated Nanoparticles with Lipid Bilayers: Effect of
Ligand Flexibility. J Phys Chem A. 2014; doi: 10.1021/jp411662c
30. Lin J, Zhang H, Chen Z, Zheng Y. Penetration of Lipid Membranes by Gold Nanoparticles: Insights into
Cellular Uptake, Cytotoxicity, and Their Relationship. ACS Nano. 2010; 4: 5421–5429. doi: 10.1021/
nn1010792 PMID: 20799717
31. Tatur S, Maccarini M, Barker R, Nelson A, Fragneto G. Effect of Functionalized Gold Nanoparticles on
Floating Lipid Bilayers. Langmuir. 2013; 29: 6606–6614. doi: 10.1021/la401074y PMID: 23638939
32. Sreekanthreddy P, Gromnicova R, Davies H, Phillips J, Romero IA, Male D. A three-dimensional model
of the human blood-brain barrier to analyse the transport of nanoparticles and astrocyte/endothelial
interactions. F1000Research. 2015; 4. doi: 10.12688/f1000research.7142.1
33. Satchell SC, Tasman CH, Singh A, Ni L, Geelen J, von Ruhland CJ, et al. Conditionally immortalized
human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int. 2006;
69: 1633–40. doi: 10.1038/sj.ki.5000277 PMID: 16557232
34. Weksler B, Romero IA, Couraud P-O. The hCMEC/D3 cell line as a model of the human blood brain
barrier. Fluids Barriers CNS. 2013; 10: 16. doi: 10.1186/2045-8118-10-16 PMID: 23531482
35. Ebong EE, Macaluso FP, Spray DC, Tarbell JM. Imaging the endothelial glycocalyx in vitro by rapid
freezing/freeze substitution transmission electron microscopy. Arterioscler Thromb Vasc Biol. 2011;
31: 1908–15. doi: 10.1161/ATVBAHA.111.225268 PMID: 21474821
36. van den Berg BM, Vink H, Spaan JAE. The endothelial glycocalyx protects against myocardial edema.
Circ Res. 2003; 92: 592–4. doi: 10.1161/01.RES.0000065917.53950.75 PMID: 12637366
37. van Haaren PMA, VanBavel E, Vink H, Spaan JAE. Localization of the permeability barrier to solutes in
isolated arteries by confocal microscopy. Am J Physiol Heart Circ Physiol. 2003; 285: H2848–56. doi:
10.1152/ajpheart.00117.2003 PMID: 12907418
38. Yuan S, Rigor R. Structure and Function of ExchangeMicrovessels. Regulation of Endothelial Barrier
Function. Morgan & Claypool Life Sciences; 2010. Available: http://www.ncbi.nlm.nih.gov/books/
NBK54123/
39. Potter DR, Damiano ER. The hydrodynamically relevant endothelial cell glycocalyx observed in vivo is
absent in vitro. Circ Res. 2008; 102: 770–6. doi: 10.1161/CIRCRESAHA.107.160226 PMID: 18258858
40. dos SantosWL, Rahman J, Klein N, Male DK. Distribution and analysis of surface charge on brain
endothelium in vitro and in situ. Acta Neuropathol. 1995; 90: 305–11. Available: http://www.ncbi.nlm.
nih.gov/pubmed/8525805 PMID: 8525805
41. Herrman G, Missfelder H, Spanel-Borowski K. Lectin binding patterns in two cultured endothelial cell
types derived from bovine corpus luteum. Histochem Cell Biol. 1996; 105: 129–37. Available: http://
www.ncbi.nlm.nih.gov/pubmed/8852434 PMID: 8852434
42. Simionescu M, Simionescu N, Palade GE. Differentiated microdomains on the luminal surface of capil-
lary endothelium: distribution of lectin receptors. J Cell Biol. 1982; 94: 406–13. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=2112875&tool=pmcentrez&rendertype=abstract PMID:
7107706
43. Holthöfer H, Virtanen I, Kariniemi AL, Hormia M, Linder E, Miettinen A. Ulex europaeus I lectin as a
marker for vascular endothelium in human tissues. Lab Invest. 1982; 47: 60–6. Available: http://www.
ncbi.nlm.nih.gov/pubmed/6177923 PMID: 6177923
44. Atukorale PU, Yang Y-S, Bekdemir A, Carney RP, Silva PJ, Watson N, et al. Influence of the glycocalyx
and plasmamembrane composition on amphiphilic gold nanoparticle association with erythrocytes.
Nanoscale. Royal Society of Chemistry; 2015; 7: 11420–11432. doi: 10.1039/C5NR01355K
45. Squire JM, ChewM, Nneji G, Neal C, Barry J, Michel C. Quasi-Periodic Substructure in the Microvessel
Endothelial Glycocalyx: A Possible Explanation for Molecular Filtering? J Struct Biol. 2001; 136: 239–
255. doi: 10.1006/jsbi.2002.4441 PMID: 12051903
46. Romero IA, Radewicz K, Jubin E, Michel CC, Greenwood J, Couraud P-O, et al. Changes in cytoskele-
tal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in
cultured rat brain endothelial cells. Neurosci Lett. 2003; 344: 112–6. Available: http://www.ncbi.nlm.nih.
gov/pubmed/12782340 PMID: 12782340
47. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-
specific properties of a human adult brain endothelial cell line. FASEB J. 2005; 19: 1872–4. doi: 10.
1096/fj.04-3458fje PMID: 16141364
Transport of Gold Nanoparticles by Vascular Endothelium
PLOSONE | DOI:10.1371/journal.pone.0161610 August 25, 2016 17 / 17
